Last reviewed · How we verify

WX-0593 Tablets — Competitive Intelligence Brief

WX-0593 Tablets (WX-0593 Tablets) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIF-1α inhibitor. Area: Oncology.

phase 3 HIF-1α inhibitor HIF-1α Oncology Small molecule Live · refreshed every 30 min

Target snapshot

WX-0593 Tablets (WX-0593 Tablets) — Qilu Pharmaceutical Co., Ltd.. WX-0593 Tablets is a small molecule drug that targets the HIF-1α pathway.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
WX-0593 Tablets TARGET WX-0593 Tablets Qilu Pharmaceutical Co., Ltd. phase 3 HIF-1α inhibitor HIF-1α
ZX-7101A for oral suspension ZX-7101A for oral suspension Nanjing Zenshine Pharmaceuticals phase 3 HIF-1α inhibitor HIF-1α
PK101-002 PK101-002 PMG Pharm Co., Ltd phase 3 HIF-1α inhibitor HIF-1α

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIF-1α inhibitor class)

  1. Boryung Pharmaceutical Co., Ltd · 1 drug in this class
  2. Fujian Akeylink Biotechnology Co., Ltd. · 1 drug in this class
  3. Nanjing Zenshine Pharmaceuticals · 1 drug in this class
  4. PMG Pharm Co., Ltd · 1 drug in this class
  5. Qilu Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). WX-0593 Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/wx-0593-tablets. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: